General Biotechnology

Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a legal strategy. In practice, it’s an engineering discipline—one that starts with reading formulation …

Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
At first glance, the two sound like cousins—both extend exclusivity, both protect revenue, both buy time. But in practice, the…

Pharmaceutical patent strategy is often discussed like a courtroom drama: file early, argue hard, win big.
But the real cost isn’t just legal fees—it’s the opportunity cost of building portfolios that look impressive on paper and fail in practice.
In a…

Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Wish They Had Earlier
Launching a drug is a sprint disguised as a marathon. The science is hard, the manufacturing is harder, and the regulatory work is relentless. But there’s one risk t…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…

Sell the line before the patent breaks.
In pharma, timing isn’t just strategy—it’s survival. The market doesn’t wait for your sales cycle, your procurement lead times, or your customer’s internal approvals. By the time a patent cliff hits, the winner…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams wait for the “cliff” to arrive—then scramble to win the scramble.
But in biologics, the cliff is predictab…

Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…

Patients aren’t asking “about patents.” They’re asking, “Will I be able to afford my medicine?”
If you’ve spent any time around drug pricing conversations lately, you’ve probably noticed a pattern: the most searched questions online rarely sound like l…

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…